NOTES TO THE COMPANY FINANCIAL STATEMENTS Continued 49.
FINANCIAL POLICIES FOR RISK MANAGEMENT AND THEIR OBJECTIVES Currency risk Currency risks as dened by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency and being of a monetary nature.
The following table illustrates financial assets and liabilities for the Company in different currencies: Liabilities Assets 2012 2011 2012 2011 $000 $000 $000 $000 Euro 36 1,992 British Pound 960 1,537 975 159 Jordanian Dinar 29 31 A sensitivity analysis based on a 1% movement in foreign exchange rates has no material impact on the Company results and Company statement of changes in equity.
Further details on how the Company manages the currency risk are given in Note 28.
Interest rate risk: An interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31December 2012, with all other variables held constant.
Based on the composition of the Company debt and cash portfolio as at 31 December 2012, a 1% increase decrease in interest rates would result in an additional interest expense income of $1,800,000 being incurred per year 2011:$1,400,000.
Liquidity risk Less than Two to More than one year five years five years Total 2012 $000 $000 $000 $000 Cash and cash equivalents 5,803 5,803 Accounts receivables 83 83 Interest-bearing loans and borrowings 35,412 99,193 63,161 197,766 Other payables 340 340 29,866 99,193 63,161 192,220 Less than Two to More than one year five years five years Total 2011 $000 $000 $000 $000 Cash and cash equivalents 6,091 6,091 Accounts receivables 92 92 Interest-bearing loans and borrowings 4,341 83,053 70,495 157,889 Other payables 412 412 1,430 83,053 70,495 152,118 The Company believes that, given the Groups forecast operating cash ow during 2012, it has the ability to satisfy its liability commitments.
STAFF COSTS Hikma Pharmaceuticals PLC currently has ten employees 2011: ten excluding Executive Directors : total compensation paid to them amounted to$2,466,000 2011: $1,890,000 of which salaries and wages compromise an amount of $1,768,000 2011: $1,291,000 the remaining balance of $698,000 2011: $599,000 represents national insurance contributions, the cost of share-based payments and other benets.
STOCK OPTIONS The details of the stock compensation scheme are provided in Note 35.
As at 31 December 2012, the total number of options granted to employees of the Company under the stock compensation scheme during the life of the scheme was 2,560,000 2011: 2,560,000 and the totalamount of the compensation expenses charged to profit and loss is $Nil 2011: $Nil.
162 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
